



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +022 2495 9595
Fax No: +022 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

8th June 2015

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Dear Sir,

Sub: Intimation under Clause 36 of the Listing Agreement

Re: Order passed by Competition Commission on June 4th 2015

This is to inform you that in 2013, a complaint was filed before the Competition Commission of India (CCI) by a local vaccine-maker Bio-Med against DADG, GlaxoSmithKline Pharmaceuticals Limited (GSK) and Sanofi; GSK filed a response controverting all the findings of the Director General- CCI. The CCI by its order dated June 4th 2015 (order copy not yet received from CCI) has held GSK and Sanofi liable for violation of the provisions of the Competition Act and levied penalty to the extent of 3% of the turnover both on GSK and Sanofi (aggregating to Rs. 60.49 crores & Rs 3.04 crores respectively)

GSK will review the said order passed by CCI. GSK is an law abiding corporate organization and operates with the highest level of integrity and in compliance with local laws, rules and regulations, including compliance with competition law and fulfillment of tender conditions. GSK did not engage in any anti-competitive activity. GSK India will consider all options following the review of the order passed by CCI and take further action (for preferring an appeal) as appropriate.

Thanking you,
GlaxoSmithKline Pharmaceuticals Limited.

Ajay Nadkarni
General Manager – Administration
& Company Secretary